OBIO icon

Orchestra BioMed

2.97 USD
+0.44
17.39%
At close Apr 30, 4:00 PM EDT
After hours
2.98
+0.01
0.34%
1 day
17.39%
5 days
5.69%
1 month
-30.61%
3 months
-46.87%
6 months
-48.26%
Year to date
-44.80%
1 year
-32.65%
5 years
-73.95%
10 years
-73.95%
 

About: Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Employees: 70

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

271% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 7

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

10% more funds holding

Funds holding: 48 [Q3] → 53 (+5) [Q4]

0.22% more ownership

Funds ownership: 50.29% [Q3] → 50.51% (+0.22%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

21% less capital invested

Capital invested by funds: $97.8M [Q3] → $76.8M (-$21M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
304%
upside
Avg. target
$14.67
394%
upside
High target
$20
573%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Chardan Capital
Keay Nakae
18% 1-year accuracy
13 / 73 met price target
573%upside
$20
Buy
Maintained
22 Apr 2025
HC Wainwright & Co.
Yi Chen
33% 1-year accuracy
57 / 173 met price target
304%upside
$12
Buy
Maintained
4 Apr 2025
BTIG
Marie Thibault
58% 1-year accuracy
7 / 12 met price target
304%upside
$12
Buy
Initiated
20 Mar 2025

Financial journalist opinion

Based on 5 articles about OBIO published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Orchestra BioMed's Virtue ® Sirolimus AngioInfusion Balloon™   (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis (“ISR”) Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025 NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational Device Exemption (“IDE”) amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial (“Virtue Trial”).
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Neutral
GlobeNewsWire
2 days ago
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences.
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Neutral
GlobeNewsWire
1 week ago
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company's atrioventricular interval modulation (“AVIM”) therapy program.
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
Neutral
GlobeNewsWire
1 week ago
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
Neutral
Zacks Investment Research
4 weeks ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
4 weeks ago
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update.
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Neutral
GlobeNewsWire
2 months ago
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.
Orchestra BioMed to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio.
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
Neutral
GlobeNewsWire
2 months ago
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
Neutral
GlobeNewsWire
2 months ago
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach.
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
Charts implemented using Lightweight Charts™